Simple method for evaluation of planum temporale pyramidal neurons shrinkage in postmortem tissue of Alzheimer disease patients. 17
Meta-analysis of the rs2075650 polymorphism and risk of Alzheimer disease. 14
Various MRS application tools for Alzheimer disease and mild cognitive impairment. 13
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. 13
Diagnostic Significance of Cortical Superficial Siderosis for Alzheimer Disease in Patients with Cognitive Impairment. 12
A Turkish 3-center study evaluation of serum folic acid and vitamin B12 levels in Alzheimer disease. 12
R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study. 10
Pre-clinical cognitive phenotypes for Alzheimer disease: a latent profile approach. 10
Age-related iron deposition in the basal ganglia of controls and Alzheimer disease patients quantified using susceptibility weighted imaging. 10
Alzheimer disease and cognitive impairment associated with diabetes mellitus type 2: associations and a hypothesis. 10
Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease. 10
Alteration of mTOR signaling occurs early in the progression of Alzheimer disease (AD): analysis of brain from subjects with pre-clinical AD, amnestic mild cognitive impairment and late-stage AD. 9
Age-specific incidence rates for dementia and Alzheimer disease in NIA-LOAD/NCRAD and EFIGA families: National Institute on Aging Genetics Initiative for Late-Onset Alzheimer Disease/National Cell Repository for Alzheimer Disease (NIA-LOAD/NCRAD) and Estudio Familiar de Influencia Genetica en Alzheimer (EFIGA). 9
Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. 8
A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease. 8
Regional neuronal network failure and cognition in late-onset sporadic Alzheimer disease. 8
A test of lens opacity as an indicator of preclinical Alzheimer Disease. 8
Neuropathologic assessment of participants in two multi-center longitudinal observational studies: the Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN). 8
mNos2 deletion and human NOS2 replacement in Alzheimer disease models. 7
Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. 7
Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). 7
Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. 6
Alzheimer disease in a mouse model: MR imaging-guided focused ultrasound targeted to the hippocampus opens the blood-brain barrier and improves pathologic abnormalities and behavior. 6
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. 6
Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. 6
[Possibilities of modern imaging technologies in early diagnosis of Alzheimer disease]. 6
The Na+/H+ exchanger NHE6 modulates endosomal pH to control processing of amyloid precursor protein in a cell culture model of Alzheimer disease. 6
Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. 6
Criminal behavior in frontotemporal dementia and Alzheimer disease. 5
Genetic Analysis of Association Between Calcium Signaling and Hippocampal Activation, Memory Performance in the Young and Old, and Risk for Sporadic Alzheimer Disease. 5
Chronic neurodegeneration after traumatic brain injury: Alzheimer disease, chronic traumatic encephalopathy, or persistent neuroinflammation? 5
Prion Disease Induces Alzheimer Disease-Like Neuropathologic Changes. 5
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. 5
Effect of Cognitive Reserve on Age-Related Changes in Cerebrospinal Fluid Biomarkers of Alzheimer Disease. 5
Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice. 5
Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. 5
"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis. 5
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease. 5
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease. 4
Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease. 4
Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results. 4
Low cardiac index is associated with incident dementia and Alzheimer disease: the Framingham Heart Study. 4
Possibility of Acetylcholinesterase Overexpression in Alzheimer Disease Patients after Therapy with Acetylcholinesterase Inhibitors. 4
Grey matter atrophy in mild cognitive impairment / early Alzheimer disease associated with delusions: a voxel-based morphometry study. 4
Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. 4
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. 4
Raloxifene for women with Alzheimer disease: A randomized controlled pilot trial. 4
Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. 4
PART is part of Alzheimer disease. 4
A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid β in the brain in a transgenic model of Alzheimer disease. 4
Retromer in Alzheimer disease, Parkinson disease and other neurological disorders. 4
Prevalence and clinicoradiological analyses of patients with Alzheimer disease coexisting multiple microbleeds. 4
Truncated Amyloid-β(11-40/42) from Alzheimer Disease Binds Cu2+ with a Femtomolar Affinity and Influences Fiber Assembly. 4
Microbleeds, Mortality, and Stroke in Alzheimer Disease: The MISTRAL Study. 4
Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. 4
Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family. 4
Mild cognitive impairment due to alzheimer disease is less likely under the age of 65. 4
Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum. 4
Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. 4
Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease. 4
Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. 3
An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. 3
Posterior cortical atrophy: an atypical variant of Alzheimer disease. 3
Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease. 3
Alzheimer disease and anesthesia. 3
Depression and synaptic zinc regulation in Alzheimer disease, dementia with lewy bodies, and Parkinson disease dementia. 3
The Link Between Physical Activity and Cognitive Dysfunction in Alzheimer Disease. 3
Distinctive Effect of Donepezil Treatment on P300 and N200 Subcomponents of Auditory Event-Related Evoked Potentials in Alzheimer Disease Patients. 3
Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. 3
Role of autophagy in the pathogenesis of Alzheimer disease. 3
Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain. 3
Cognitive intervention therapy as treatment for behaviour disorders in Alzheimer disease: evidence on efficacy and neurobiological correlations. 3
APOEε2 is associated with milder clinical and pathological Alzheimer disease. 3
Public perceptions of presymptomatic testing for Alzheimer disease. 3
Association of Insulin Resistance With Cerebral Glucose Uptake in Late Middle-Aged Adults at Risk for Alzheimer Disease. 3
Reelin signaling pathway genotypes and Alzheimer disease in a Spanish population. 3
Role of the extended MAPT haplotype in the worsening of psychotic symptoms and treatment response in Alzheimer disease. 3
Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease. 3
The complexities of the pathology-pathogenesis relationship in Alzheimer disease. 3
Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. 2
Medial temporal lobe atrophy and depressive symptoms in elderly patients with and without Alzheimer disease. 2
Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions. 2
Neurobiology of delusions, memory, and insight in Alzheimer disease. 2
Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes. 2
Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS). 2
Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study. 2
Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. 2
A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. 2
Cerebellum Can Serve As a Pseudo-Reference Region in Alzheimer Disease to Detect Neuroinflammation Measured with PET Radioligand Binding to Translocator Protein. 2
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. 2
Relationships between testosterone levels and cognition in patients with Alzheimer disease and nondemented elderly men. 2
Frontal Lobe Function and Risk of Hip Fracture in Patient With Alzheimer Disease: An Analysis of Linked Data. 2
18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. 2
Diagnosis of mild Alzheimer disease through the analysis of eye movements during reading. 2
Targeting Prodromal Alzheimer Disease With Avagacestat: A Randomized Clinical Trial. 2
Decreasing oxidative stress and neuroinflammation with a multifunctional peptide rescues memory deficits in mice with Alzheimer disease. 2
Dementia in 2014. Towards early diagnosis in Alzheimer disease. 2
Statin Use, Incident Dementia and Alzheimer Disease in Elderly African Americans. 2
Common Polymorphisms in the GSK3β Gene May Contribute to the Pathogenesis of Alzheimer Disease: A Meta-Analysis. 2
Angiotensin converting enzyme inhibitors and Alzheimer disease in the presence of the apolipoprotein E4 allele. 2
Why is Alzheimer disease confused with other dementias? 2
Anosognosia in Alzheimer disease: Disconnection between memory and self-related brain networks. 2
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE. 2
Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease. 2
A randomized cross-over controlled study on cognitive rehabilitation of instrumental activities of daily living in Alzheimer disease. 2
Potential roles of PINK1 for increased PGC-1α-mediated mitochondrial fatty acid oxidation and their associations with Alzheimer disease and diabetes. 2
Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease. 2
Gracilins: Spongionella-derived promising compounds for Alzheimer disease. 2
A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. 2
The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease. 2
Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. 2
Novel potential for the management of Alzheimer disease. 2
Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. 2
Alzheimer disease: the landscape of ageing--insights from AD imaging markers. 2
The lower hippocampus global connectivity, the higher its local metabolism in Alzheimer disease. 2
Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. 2
Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. 2
The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation. 2
Association between polymorphisms of the insulin-degrading enzyme gene and late-onset Alzheimer disease. 2
The mitochondrial O-linked N-acetylglucosamine transferase (mOGT) in the diabetic patient could be the initial trigger to develop Alzheimer disease. 2
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. 2
The Effect of Reminiscence Therapy on Cognition, Depression, and Activities of Daily Living for Patients With Alzheimer Disease. 1
Clinical Significance of Cerebrovascular Biomarkers and White Matter Tract Integrity in Alzheimer Disease: Clinical correlations With Neurobehavioral Data in Cross-Sectional and After 18 Months Follow-ups. 1
Does past or present depression differentiate Lewy body from Alzheimer disease? 0
The Human Alzheimer Disease Project: A New Call to Arms. 0
Midlife personality and risk of Alzheimer disease and distress: A 38-year follow-up. 0
Alzheimer disease: Alzheimer dementia with sparse amyloid-AD mimic or variant? 0
Is dominantly inherited Alzheimer disease a clone of sporadic Alzheimer disease? 0
